So, here's the thing about being an eye care company: when you launch new tech that actually works, people notice. That's the story at Alcon Inc. (ALC), which just reported third-quarter results that sent its stock climbing nearly 5%.

The numbers: sales came in at $2.59 billion. That's up 6% from a year ago, which is solid growth. It did, however, just barely miss the consensus estimate of $2.60 billion. But in the grand scheme of things, that's a rounding error. The more important figure was the bottom line. Adjusted earnings hit 79 cents per share, beating the Street's expectation of 76 cents. Sometimes it's not about the top line; it's about what you do with it.

"As expected, we saw encouraging topline growth in the third quarter, driven by strong acceleration in equipment," said CEO David J. Endicott. He pointed to specific products gaining momentum: "Unity VCS is gaining traction across key markets, and our orderbook remains strong. With PanOptix Pro resonating well with surgeons and early uptake of Tryptyr showing promise, we're laying the groundwork for a solid 2026."

Let's break down where the money came from. The business is split into two main segments: Surgical and Vision Care.

Surgical net sales, which is everything from implantables to the big machines, brought in $1.42 billion. That's a 6% increase on a reported basis. Vision Care, which covers contact lenses and ocular health products, posted $1.2 billion in sales, a 7% increase.

Now, the profitability picture is a bit more mixed. Core operating income was $523 million, up 4%. However, the core operating margin dipped slightly to 20.20%, down 0.4 percentage points from the prior year. The company attributed this to a few factors: new tariffs, increased spending on sales and marketing to launch those new products Endicott mentioned, and more investment in research and development. They did manage to offset some of that pressure with manufacturing efficiencies and price increases, but the margin squeeze is a reality they're navigating.

Looking ahead, Alcon isn't changing its tune. The company affirmed its fiscal year 2025 outlook. They still expect adjusted earnings per share in the range of $3.05 to $3.15, which brackets the consensus estimate of $3.06. Sales guidance is also unchanged at $10.3 billion to $10.4 billion, compared to a consensus of $10.39 billion. They see the core operating margin landing between 19.5% and 20.5% for the full year.

In the end, the market seemed to focus on the earnings beat and the promising product commentary rather than the slight revenue miss. Shares were up 4.91% at $81.15 following the report. It appears investors are buying the story that Alcon's new eye tech isn't just a flash in the pan—it's building a foundation for the future.